(FULC) – New Coverage
-
RBC Capital Starts Fulcrum Therapeutics (FULC) at Outperform, 'A Rare Disease Pipeline with Its DUX in a Row'
-
Goldman Sachs Starts Fulcrum Therapeutics (FULC) at Neutral, 'Value limited to near-term losmapimod sales'
-
-
-
-
-
-
-
-
-
-
-
Back to FULC Stock Lookup